Izopet J, Rostaing L, Mousion F, That HT, Payen JL, et al
Long-term virological response after alpha-interferon therapy
in HCV-positive hemodialysis patients
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Nov) 6:537 1995
There is little experience with treatment of HCV infection in
hemodialyzed patients with alpha-interferon. In this study 12
hemodialyzed patients with chronic active hepatitis due to HCV
were treated with alpha-interferon for 24 weeks. 7 of these had
increased aminotransferase activities before treatment. Most of
the HCV genotypes were 1b or 2a. At the end of treatment serum
transaminases fell to normal levels in 85%. HCV RNA was
undetectable in all patients except 1. The suppression of HCV
viremia continued on for 18 months of follow-up in 7 of the
patients without further therapy. Viremia did appear in 1
patient 21 months after beginning of treatment. The conclusion
of this study is that alpha-interferon is well tolerated in
hemodialysis patients with HCV and deserves further clinical
trials.
(Daugirdas)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
CRF by organ system :
GI/Liver, Hepatitis